X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (15) 15
humans (15) 15
index medicus (15) 15
middle aged (14) 14
adult (13) 13
aged (11) 11
breast cancer (11) 11
oncology (11) 11
cancer (9) 9
chemotherapy (9) 9
metastasis (9) 9
prognosis (9) 9
disease-free survival (8) 8
hematology, oncology and palliative medicine (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
analysis (6) 6
chemotherapy, adjuvant (6) 6
immunohistochemistry (6) 6
medical colleges (6) 6
treatment outcome (6) 6
antimitotic agents (5) 5
antineoplastic agents (5) 5
breast neoplasms - drug therapy (5) 5
breast neoplasms - pathology (5) 5
kaplan-meier estimate (5) 5
product development (5) 5
therapy (5) 5
aged, 80 and over (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
cancer therapies (4) 4
combination (4) 4
expression (4) 4
invasion (4) 4
male (4) 4
mutation (4) 4
proportional hazards models (4) 4
receptor, erbb-2 - metabolism (4) 4
resistance (4) 4
triple negative breast neoplasms - pathology (4) 4
tumors (4) 4
adjuvant chemotherapy (3) 3
biomarkers, tumor - analysis (3) 3
biomedicine (3) 3
breast neoplasms - genetics (3) 3
breast neoplasms - mortality (3) 3
cancer research (3) 3
carcinoma (3) 3
care and treatment (3) 3
clinical trials (3) 3
lymphatic metastasis (3) 3
neoplasm invasiveness (3) 3
neoplasm metastasis (3) 3
neoplasm recurrence, local - pathology (3) 3
neoplasm staging (3) 3
sirt1 (3) 3
triple negative breast cancer (3) 3
triple negative breast neoplasms - mortality (3) 3
young adult (3) 3
adjuvant treatment (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
aromatase inhibitors (2) 2
bevacizumab (2) 2
biliary tract cancer (2) 2
biomarkers, tumor - genetics (2) 2
biomarkers, tumor - metabolism (2) 2
blotting, western (2) 2
breast neoplasms - chemistry (2) 2
breast neoplasms - enzymology (2) 2
breast neoplasms - surgery (2) 2
capecitabine (2) 2
carcinoma, ductal, breast - enzymology (2) 2
carcinoma, ductal, breast - mortality (2) 2
carcinoma, ductal, breast - secondary (2) 2
cell cycle (2) 2
cell line, tumor (2) 2
cell-migration (2) 2
class i phosphatidylinositol 3-kinases (2) 2
clinical outcomes (2) 2
docetaxel (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
endocrine therapy (2) 2
estradiol - administration & dosage (2) 2
estradiol - analogs & derivatives (2) 2
fluorouracil - administration & dosage (2) 2
gene amplification (2) 2
gene expression (2) 2
growth (2) 2
health aspects (2) 2
hormones (2) 2
infusions, intravenous (2) 2
lapatinib (2) 2
lymph node metastasis (2) 2
medical prognosis (2) 2
multivariate analysis (2) 2
mutations (2) 2
neoadjuvant therapy (2) 2
neoplasm invasiveness - pathology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 791 - 800
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 25 - 32
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1225 - 1233
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 933 - 942
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 357 - 366
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Journal Article
Tumor Biology, ISSN 1010-4283, 4/2016, Volume 37, Issue 4, pp. 4743 - 4753
Journal Article
Human Pathology, ISSN 0046-8177, 2015, Volume 46, Issue 7, pp. 1027 - 1035
Journal Article
Clinical & Experimental Metastasis, ISSN 0262-0898, 2/2016, Volume 33, Issue 2, pp. 179 - 185
Journal Article